ScinoPharm to Invest in Tanvex Biologics

TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ — ScinoPharm, a leading active
pharmaceutical ingredient (API) developer and manufacturer headquartered in
Taiwan, today announced an investment into Tanvex Biologics, Inc., a United
States company registered in the State of Delaware. ScinoPharm’s investment
was in the form of tangible assets, intellectual properties, as well as cash.

Tanvex specializes in the development of biosimilars and biobetters, as
well as the provision of contract research and contract manufacturing services
for biologics. The company is currently establishing a cGMP facility in San
Diego, California and will have research centers in both the U.S. and Taiwan.
Tanvex is founded by Dr. Allen Chao, the founder and former Chairman and Chief
Executive Officer of Watson Pharmaceuticals, Inc.

Dr. Hardy Chan, co-founder and Chief Scientific Officer of ScinoPharm,
will become the Chief Executive Officer of Tanvex. Dr. Chao will remain as
Executive Chairman of Tanvex.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing
service provider to the global pharmaceutical industry. With research and
manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers
a wide portfolio of services ranging from custom synthesis for early phase
pharmaceutical activities to brand companies as well as APIs for the generic
industry. For more information, please visit http://www.scinopharm.com .

About Tanvex Biologics

Tanvex Biologics, LLC is a US-based biopharmaceutical company specializing
in the development of biopharmaceuticals.

    Media Contact:

    ScinoPharm Taiwan, Ltd.
     Sabrian Wu
     Tel: +886-6-505-2869
     Mobile Phone: +886-920-056-385
     Email: sabrina.wu@scinopharm.com.tw

SOURCE ScinoPharm Taiwan, Ltd.